1. Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice
- Author
-
Mark S. Geier, Hans-Ulrich Demuth, Gordon S. Howarth, Roger Yazbeck, and Catherine A. Abbott
- Subjects
Dipeptidyl-Peptidase IV Inhibitors ,business.industry ,Dipeptidyl Peptidase 4 ,Growth factor ,medicine.medical_treatment ,Crypt ,Dipeptidyl-peptidase activity ,Inflammatory Bowel Diseases ,Pharmacology ,Colitis ,medicine.disease ,Ulcerative colitis ,digestive system diseases ,Disease Models, Animal ,Kinetics ,Mice ,medicine ,Animals ,Dipeptidyl-Peptidases and Tripeptidyl-Peptidases ,business ,Saline ,Dipeptidyl peptidase-4 - Abstract
New treatment strategies are required for the debilitating inflammatory bowel diseases (IBD), Crohn's Disease and Ulcerative Colitis. DP inhibitors can prolong the bioactivity of the potent intestinotrophic growth factor glucagon-like peptide-2 (GLP-2(1-33)). We investigated whether novel inhibitors of DP activity could modify the course of disease activity in the dextran sulfate sodium (DSS) model of colitis. C57BL/6 mice consumed 2 percent DSS in drinking water for 6 days. Mice were orally gavaged twice daily with 0.9% saline, 10 mg/kg isoleucyl-cyano-pyrrolidine (P59/99) or isoleucyl-thiazolidine (P32/98). Assessment of disease severity incorporated a disease activity index (DAI), together with histological assessment of crypt area and depth in the distal colon. DP activity was significantly inhibited at all time points. The DAI was significantly lower in the P59/99 and P32/98 treatment groups compared to saline treatment in all three time courses. Crypt hyperplasia (p
- Published
- 2008
- Full Text
- View/download PDF